Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORMER: BAT vs Enzalutamide in mCRPC
NCT02286921Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of testosterone cypionate and testosterone enanthate in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Progression Free Survival up to 2 years. Started Jan 2015; status: completed.
02
Drugs
testosterone cypionatetestosterone enanthate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02286921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286921.